Agenus (AGEN) shares ended the last trading session 19.3% higher at $7.06. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 22.8% gain over the past four weeks.Earlier this month, the company announced encouraging clinical data for its combination therapy of botensilimab and balstilimab (BOT/BAL) in patients with microsatellite-stable metastatic colorectal cancer without active liver metastases. In an expanded cohor ...

Core Insights - The focus on steady earnings growth is essential for assessing a company's profitability, but rapid earnings growth can significantly drive stock prices higher [1] - Research indicates that stocks with accelerating earnings often see their prices increase subsequently [1] Earnings Acceleration - Earnings acceleration refers to the incremental growth in a company's earnings per share (EPS), characterized by an increase in quarter-over-quarter earnings growth rates [3] - This metric helps identify stocks that have not yet attracted investor attention, potentially leading to a price rally once recognized [4] Screening Parameters - The screening process involves identifying stocks where the last two quarter-over-quarter EPS growth rates exceed previous periods' growth rates, with projected EPS growth rates for the upcoming quarter expected to surpass prior periods [6][7][8] - Additional criteria include a current price of at least $5 and an average 20-day trading volume of 50,000 or more to ensure adequate liquidity [8] Identified Stocks - The screening narrowed down to three stocks: Yext, Agenus, and NCR Voyix, all showing strong earnings acceleration [9] - NCR Voyix leads with an expected EPS growth rate of 152.7%, followed by Agenus at 114.7% and Yext at 37.1% for the current year [9] Company Profiles - **Yext**: Provides a platform for consumer inquiries globally, with an expected earnings growth rate of 37.1% [10] - **Agenus**: A biotechnology firm focused on developing immune therapies for cancer and infections, with an expected earnings growth rate of 114.7% [11] - **NCR Voyix**: Offers digital commerce solutions for retail and dining, with an expected earnings growth rate of 152.7% [12]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CVS Health (CVS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.CVS Health is a member of our Medical group, which includes 996 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 1 ...

After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving avera ...

On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.’s AGEN U.S.-based biologics CMC facilities.The acquisition marks Zydus’ strategic investment in U.S.-based biologics manufacturing, thereby adding a sustainable growth driver for the group.Agenus is a clinical-stage immuno-oncology company.Zydus will acquire two biologics manufacturing facilities from Agenus in Emeryvill ...

Shares of Agenus (AGEN) have gained 68.4% over the past four weeks to close the last trading session at $5, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.33 indicates a potential upside of 26.6%.The mean estimate comprises three short-term price targets with a standard deviation of $2.08. While the lowest estimate of $4 indicates a 20% decline from the current price level, ...

Summary of Agenus Inc. Investor Briefing Call Company Overview - **Company**: Agenus Inc. (AGEN) - **Industry**: Biotechnology, specifically focused on immuno-oncology and cancer treatments Key Points and Arguments 1. **Strategic Collaboration**: Agenus announced a strategic collaboration with Zydis Life Sciences, aimed at enhancing their capabilities in cancer treatment and expanding their market reach [2][12][14] 2. **Colorectal Cancer Statistics**: Colorectal cancer (CRC) incidences have doubled in the U.S. among adults under 50 since 1995, projected to become the leading cause of cancer-related deaths in men by 2030 [5][6] 3. **Regulatory Environment**: The new leadership at HHS and the FDA is focused on accelerating the approval of meaningful treatments, which is seen as a positive shift for the research community [7][8] 4. **Clinical Data**: Agenus is generating compelling data for their treatments, particularly Botanosorimab and Balstotamab (BotBal), showing effectiveness across various cancer types, including MSS colorectal cancer and triple-negative breast cancer [9][10][11] 5. **Leadership Addition**: Dr. Richard Goldberg, a GI oncology expert, has joined as Chief Development Officer to support the next phase of development [12] 6. **Market Opportunities**: The partnership with Zydis is expected to enhance supply chain reliability and operational efficiency, particularly in the U.S. and India [13][15][17] 7. **Financial Structure**: The deal includes a $75 million upfront payment and up to €50 million in contingent payments, with additional land assets valued at €40-50 million to be divested [21][22] 8. **Cost Management**: Operating burn is projected at $50 million annually, with clinical trial costs for CRC expected to be approximately $25 million over three years [53][72] 9. **Clinical Trials**: Plans to initiate registration trials for CRC this year, with a focus on both late-stage and neoadjuvant settings [70][72] 10. **Patient Impact**: The goal is to provide innovative treatments that improve patient quality of life, particularly for those who currently face harsh side effects from traditional therapies [72] Additional Important Content - **Emerging Markets**: The collaboration with Zydis will leverage their extensive clinical trial networks in India, which is less competitive for certain cancer treatments [27][38] - **Immunotherapy Market**: The partnership aims to unlock a $50 billion global market segment in immunotherapy, which currently reaches less than one-third of eligible patients [28] - **Future Plans**: Agenus is focused on expanding its research and development capabilities while ensuring that innovations reach patients efficiently [24][30] - **Shareholder Engagement**: A call to action for shareholders to participate in upcoming meetings and support the team’s efforts [31][78] This summary encapsulates the critical aspects of the investor briefing call, highlighting the strategic direction, clinical advancements, and financial outlook of Agenus Inc.

Core Insights - The article discusses the investment potential of Agenus (NASDAQ: AGEN), suggesting that the market has overreacted to selling pressures on the company's stock [1]. Group 1 - The author has been following Agenus for over a year and a half, indicating a long-term interest in the company's performance [1]. - The investment focus is on innovative companies in the biotech sector that are developing breakthrough therapies and pharmaceuticals [1]. - The article is part of a subscription marketplace service called Compounding Healthcare, which offers various investment resources [1]. Group 2 - The author holds a beneficial long position in Agenus shares, either through stock ownership or derivatives [2]. - The article reflects the author's personal opinions and is not influenced by any business relationships with the company mentioned [2].

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than the traditional "buying low and selling high" strategy, aiming for quicker profits [1] Group 1: Momentum Investing Characteristics - Fast-moving trending stocks can be difficult to enter at the right time, as they may lose momentum if future growth does not justify their high valuations [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify these opportunities [3] Group 2: Case Study - Agenus (AGEN) - Agenus (AGEN) has shown significant recent price momentum with a four-week price change of 67.3%, indicating strong investor interest [4] - The stock has gained 4.8% over the past 12 weeks and has a beta of 1.48, suggesting it moves 48% more than the market [5] - AGEN has a Momentum Score of A, indicating a favorable time to invest based on momentum [6] Group 3: Earnings Estimates and Valuation - AGEN has seen upward revisions in earnings estimates, earning a Zacks Rank 2 (Buy), which typically attracts more investor interest [7] - The stock is currently trading at a Price-to-Sales ratio of 0.96, suggesting it is undervalued as investors pay only 96 cents for each dollar of sales [7] Group 4: Additional Opportunities - Besides AGEN, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies to help identify potential winning stocks based on various investing styles [9]

Company Overview - The company is a clinical-stage biotechnology firm focused on immuno-oncology, with a diverse pipeline including immune-modulatory antibodies and adoptive cell therapies[91]. Lead Programs and Collaborations - The lead program, botensilimab (BOT), is progressing through multiple clinical programs and has received Fast Track designation from the FDA for treating non-MSI-H and/or dMMR metastatic colorectal cancer[94]. - The company has collaborations with several firms, including Bristol-Myers Squibb and Merck, resulting in over a dozen antibody pre-clinical or clinical development programs[95]. - The collaboration with Incyte includes potential milestone payments of up to $315 million, but Incyte has terminated several programs, reverting rights back to the company[96]. - The company received a non-refundable upfront payment of $200 million from Bristol-Myers Squibb for the AGEN1777 program, with additional milestones achieved[102]. - The company has entered into a Purchase and Sale Agreement with Ligand Pharmaceuticals, which includes a synthetic royalty on worldwide net sales of BOT and BAL[104]. - The company launched SaponiQx to innovate in adjuvant discovery and vaccine design, focusing on saponin-based adjuvants[105]. - The QS-21 adjuvant is partnered with GSK, contributing to multiple vaccine programs, with milestone payments received based on GSK's sales exceeding specified thresholds[106]. - MiNK, a subsidiary, completed an IPO and is developing allogeneic iNKT cell therapies, with a $5.8 million private placement financing secured for clinical development[107]. - The company aims to expand its market presence through strategic partnerships and collaborations for product development and commercialization[108]. Financial Performance - Non-cash royalty revenue from GSK decreased by $4.2 million to approximately $23.6 million for Q1 2025, down from $27.8 million in Q1 2024, due to decreased net sales of GSK's vaccines[110]. - Research and development expenses decreased by 51% to $21.5 million for Q1 2025, down from $43.9 million in Q1 2024, primarily due to a $16.3 million decrease in third-party services[111]. - General and administrative expenses decreased by 7% to $15.7 million for Q1 2025, down from $16.9 million in Q1 2024, mainly due to a $1.5 million decrease in personnel-related expenses[112]. - Interest expense, net decreased to approximately $12.8 million for Q1 2025 from $29.5 million in Q1 2024, primarily due to decreased non-cash interest related to the Royalty Purchase Agreement with HCR[113]. - Cash and cash equivalents as of March 31, 2025, were $18.5 million, a decrease of $21.9 million from December 31, 2024[119]. - The company had an accumulated deficit of $2.2 billion as of March 31, 2025, and expects to incur significant losses over the next several years[117]. - Net cash used in operating activities for Q1 2025 was $25.6 million, compared to $38.2 million in Q1 2024[125]. - The company has raised approximately $2.01 billion through various financing methods since inception, including equity sales and royalty monetization[117]. - The company plans to enter into additional agreements with third-party providers, estimating total payments of $660.7 million over the term of related activities[123]. - As of March 31, 2025, the company had outstanding debt of $36.0 million, with $10.5 million due in June 2026 and $24.75 million due in November 2026[120].